Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly yuglitazone tablets as monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and exercise
CTR20213059Phase 3Completed
- Sponsor
- Chengdu Yuantong Pharmaceutical
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of yuglitazone in type 2 diabetes mellitus (T2DM), sponsored by Chengdu Yuantong Pharmaceutical. Started Nov 2021; status: completed.
02
Drugs
yuglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20213059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213059.